Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/15/2019 02/19/2019 02/20/2019 02/21/2019 02/22/2019 Date
56.65(c) 56.81(c) 60.53(c) 58.26(c) 59.82(c) Last
466 454 537 607 1 064 319 927 922 416 272 Volume
+2.15% +0.28% +6.55% -3.75% +2.68% Change
More quotes
Financials (USD)
Sales 2019 101 M
EBIT 2019 -359 M
Net income 2019 -345 M
Finance 2019 163 M
Yield 2019 -
Sales 2020 212 M
EBIT 2020 -272 M
Net income 2020 -250 M
Finance 2020 234 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 28,6x
EV / Sales2020 13,4x
Capitalization 3 068 M
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics... 
More about the company
Surperformance© ratings of Ultragenyx Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on ULTRAGENYX PHARMACEUTICAL
02/22ULTRAGENYX PHARMACEUTICAL : Announces Positive 24-week Data from First Cohort of..
AQ
02/21ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
02/21ULTRAGENYX PHARMACEUTICAL : Announces Positive 24-week Data from First Cohort of..
AQ
02/20ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
02/19ULTRAGENYX : 4Q Earnings Snapshot
AQ
02/19ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
02/19Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Co..
GL
02/16Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (bu..
AQ
02/15Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : and Kyowa Kirin Announce Positive 64-Week Results fo..
AQ
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL
More recommendations
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Bio Therapeutic Drugs
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 72,8 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC37.58%3 068
GILEAD SCIENCES4.80%85 043
VERTEX PHARMACEUTICALS13.49%47 491
REGENERON PHARMACEUTICALS13.51%45 364
GENMAB0.14%9 991
SAREPTA THERAPEUTICS INC28.27%9 870